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based on revealing of xenobiotics to influence on specific
enzymes participating in epigenetic modifications, especially
DNA methylation and histone modifications. Recently a new
model system for the screening of compounds reactivating
epigenetically repressed genes was described. It represents HeLa
cell population that harbors silent GFP-reporter gene which could
be activated via different epigenetic mechanisms.
Epigenetic studies of xenobiotic-induced mechanisms will
reveal valuable information clarifying both mechanisms of desir-
able therapy and side effects and open potential drug design
directions. The major challenge that remains is to determine
how epigenetic control is regulated and how it might be possible
to intervene in such processes.
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Oncolytic virus therapy is an area in experimental cancer ther-
apy that is under active investigation. A wide variety of viruses
have shown huge potent oncolytic activity against human tumors
in cell and animal models without major side effects. Several
strains have already being tested in clinical trials in patients.
Virotherapy is making promising progress for the treatment of
malignancies. Nonetheless, when used in patients, the response
rate to oncolytic virus is low. One of the main ways to increase
oncolytic capacity is to refuse of excessive attenuation and to
use the wild type of oncolytic strains.
Naturally occurring oncolytic viruses (OVs) have shown their
high cancer-targeted antitumor effects with selectively replica-
tion and destroying tumor cells while sparing normal cells,
because of defects in IFN-signaling pathways in tumor cell lines.
Newcastle disease virus (NDV) is one of the promising thera-
peutic agent for virotherapy. It belongs to avian paramyxovirus
(APMV-1) that is able to infect over 240 species of birds and induce
severe disease. However, NDV is not a human pathogen.
Newcastle disease virus exhibits effectively oncolytic activity in
a range of tumors in pre-clinical and clinical studies. We have
previously reported in vitro oncolytic effects of three wild NDV
strains. Here we demonstrate data that describe oncolytic capac-
ity NDV collection gathered in 2008–2014, Russia. Antitumor
effect of NDV strains on a panel of tumor human cell lines
(HCT116, MCF7, A549, HeLa, Skbr, H1299) were investigated. Cell
viability was examined over 96 hours by MTT assay. Dose-
dependent cell cytotoxicity was demonstrated.
In vitro study shows the capacity of several wild NDV strains
to lyse tumor cell lines. Two strains of them have significant
strong oncolytic activity on human tumor cells of various
histogenesis.
Recent work in our research also describes the results of
in vivo experiments. One of them consists of comparing the effi-
cacy of NDV strain to exhibit specific oncolytic activity in C57Bl/6
mice on subcutaneous murine tumors (LLC and B16) . Our results
show that both intravenous and intratumoral injections with
multiple doses of wild NDV strain lead to survival prolongation
in B16- and LLC-bearing mice and prevent tumor development.
We demonstrate antitumor activity of NDV/Altai/
pigeon/770/2011 against murine KREBS-2 solid tumor in preclini-
cal model on immunocompetent BALB/c mice. Recently we have
demonstrated that NDV/Altai/pigeon/770/2011 can destroy
murine KREBS-2 cells in vitro. Moreover, in pilot study we have
shown that intratumoral NDV injections decrease of tumor
volume and result in complete regression of KREBS-2 tumor in
MRI images.
Here we test intratumoral administration of NDV and show
suppression of Krebs-2 tumor growth in intramuscularly allograft
model (2.6-fold less size that in untreated group). Importantly,
spread of the virus causes significant tumor necrosis in Krebs-2
tumors. By 20 days after virotherapy, widespread necrosis of
NDV-treated tumor is observed. We describe that the vast fields
of necrosis in NDV-treated group are the results of formation of
ischemic foci in tumor tissue with the rapid development of
tumor node and slow neoangiogenesis.
Histological examinations and morphometric analysis of
tumors in NDV-treated and control groups show that the number
of blood vessels including the newly formed in the untreated
group is significantly higher than in the experimental group.
Immunohistochemical staining (CD34, VEGFR) shows that blood
vessels in tumor tissue is strongly reduced to 20 days post-
treatment and neoangiogenesis progresses in untreated tumor
tissue.
Thus, results suggest that vascular disruption in the
NDV-treated group indicates the virus ability to directly or indi-
rectly affect tumor angiogenesis and regulate tissue trophism in
that way. Understanding how and in which step this effect occurs
may provide capacity to use oncolytic NDV strains for therapeutic
benefit.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.119
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The mechanisms of mesenchymal stem cells (MSC) action on
malignant neoplasms attract much attention nowadays. Studies
relating to the MSC effect on tumors are contradictory and
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indicate that MSC has both stimulating and suppressive actions
on experimental neoplasms. We have shown previously that a
single MSC administration to tumor-bearing animals has an
oncomodulating effect on the growth of tumors. Short-term stim-
ulation of the growth of tumor nodes initially after the MSC
injection was usually followed by subsequent deceleration of
their growth.
Here, we have studied the effects of allogeneic MSC on sar-
coma M-1 in rats. On day 11 after the sarcoma M-1 implantation,
1.5 million MSC grown from the bone marrow cell population of
Wistar rats was administered into the tail vein of outbred rats
from the experimental group. On days 17 and 30 of the tumors
growth, 10 rats from each group were used to study the sarcoma
M-1. To analyze the MSC distribution and localization in the
tumor parenchyma, on days 11 and 13, five rats in the study were
intravenously infused 2 million MSC, labeled in vitro by bromod-
eoxyuridine (BrdU). The techniques for studying of the tumor
reaction on the systemic MSC transplantation included
immunostaining for PCNA, BrdU and PECAM-1, in conjunction
with computerized analysis of the microscopic images.
One day after transplantation, the BrdU-labeled MSC localized
in the perivascular areas of angiogenesis on the periphery of
tumor nodes with the diameter of more than 6 mm, containing
foci of spontaneous necrosis. Sometimes, labeled cells could be
seen near the vessels situated deep in the tumor parenchyma.
On day 3, cells with the low-intense BrdU immunostaining were
found only rarely and mostly perivascularly. These cells were
visualized in the region of pericytes’ localization, and the low
BrdU-immunostaining intensity of their nuclei indicated the label
dilution effect.
Six days after the MSC administration, some local areas of the
connective tissue enlargements on the periphery of tumor nodes
were observed with a distinct vascular ingrowth into the tumor
parenchyma. In the same areas, the marginal region of tumor
nodes contained a considerable number of neutrophils and lym-
phocytes. The PCNA staining revealed foci of increased prolifera-
tive activity of tumor cells in these areas, as well as intensive
proliferation of fibroblasts and vascular endothelium, which
indicates the increase of angiogenesis and stroma formation.
After the MSC administration the content of parenchyma with
PCNA-positive nuclei significantly increased, whereas the volume
fraction of the necrosis regions decreased by more than 1.5 times.
On day 30 of the sarcoma M-1 growth, tumors in the experi-
mental group rats were surrounded by layers of connective tissue.
The peritumoral area was infiltrated by numerous lymphocytes
and macrophages. In the terminal period of the sarcoma growth,
the most quantitative parameters for tumors in the experimental
group did not significantly differ from the data obtained in the
control group. Only the rate of tumor cell apoptosis in animals
with transplanted MSC was statistically higher than that in
control rats.
Reviewing the literature regarding the influence of MSC on the
malignant growth revealed that this problem still remains quite
unclear and disputable. One of the contradictions is their ability
to have opposite effects on the repopulation activity of tumor
cells. The complex interactions between MSC, tumor microenvi-
ronment and neoplastic cells seem to be crucial for the outcome
of the oncological process development. Further detailed studies
of the mechanisms of the cellular therapy using MSC on carcino-
genesis are necessary to generate new insights into this area.
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Lung cancer (LC) is currently the world’s leading cause of
cancer-related mortality with overall mortality to incidence ratio
of 0.87. Only 15% of LC patients are diagnosed at early stage of dis-
ease and have 5-year survival rate of 54%, whereas 56% of
patients have distant metastases and 5-year survival rate of about
4%. Current methods of lung cancer diagnostics are not efficient
as screening tools due to high costs (CT), low sensitivity and
health risks (radiology), invasiveness (biopsy) or low prevalence
in population (genetic alterations). New strategies for preclinical
lung cancer screening as well as monitoring of post therapy
relapses are required. MiRNAs circulating in blood were shown
to reflect the progression of disease and are thus considered as
potential biomarkers for cancer diagnostics and theranostics.
In this study we investigated seven-miRNA signature circulat-
ing in plasma of lung cancer patients and healthy individuals. All
sevenmiRNAswere previously shown to be involved in either reg-
ulation of cell cycle and apoptosis and/or tumor development,
invasion and vascularization.
Blood samples of 50 healthy individuals were obtained from
Center of New Medical Technologies (Novosibirsk, Russia) and
Novosibirsk Research Institute of Circulation Pathology of E.N.
Meshalkin (Novosibirsk, Russia). Samples of 75 lung cancer
patients, including 52 patients with squamous cell carcinoma
(SCC) and 18 patients with adenocarcinoma (AC) were obtained
from Novosibirsk Research Institute of Circulation Pathology of
E.N. Meshalkin (Novosibirsk, Russia) and Tomsk Cancer Research
Institute RAMS (Tomsk, Russia). None of the patients have under-
gone surgical treatment or received chemotherapy prior to blood
collection. Lung biopsy specimens and imaging techniques were
applied to confirm the histopathological features and tumor
stages of LC patients. Study was approved by ethical committees
of all participating organizations and written informed consent
was provided by all participants.
Circulating miRNAs were isolated from blood plasma using a
single-phase phenol-free protocol (Zaporozhchenko et al., Anal
Biochem, 2015; Rus. patent application No. 2014137763, priority
date 17.09.2014). Concentrations of miRNAs (miR-21, miR-19b,
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